Loading clinical trials...
Loading clinical trials...
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Combination With Sorafenib as First Line Treatment in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Conditions
Interventions
Refametinib (BAY86-9766)
Sorafenib (BAY43-9006)
Locations
79
United States
Louisville, Kentucky, United States
Vienna, Austria
Bruxelles - Brussel, Belgium
Edegem, Belgium
Leuven, Belgium
Liège, Belgium
Start Date
September 27, 2013
Primary Completion Date
July 29, 2015
Completion Date
February 8, 2017
Last Updated
April 8, 2021
NCT06454578
NCT05870969
NCT02221778
NCT05389527
NCT05908786
NCT04732286
Lead Sponsor
Bayer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions